Enjoy complimentary customisation on priority with our Enterprise License!
The sexually transmitted disease (STD) testing market size is forecast to increase by USD 32.37 billion, at a CAGR of 5.6% between 2023 and 2028. Market growth hinges on various factors, notably the rising incidence of sexually transmitted diseases (STDs). This trend is further driven by favorable reimbursement policies and heightened governmental initiatives worldwide. The increased focus on STD prevention and treatment underscores the importance of accessible healthcare services and support systems. Furthermore, advancements in medical technology and treatment protocols contribute significantly to addressing this public health concern. The collaborative efforts between healthcare providers, policymakers, and industry stakeholders are pivotal in driving awareness, diagnosis, and treatment of STDs. These collective actions not only spur market expansion but also promote better healthcare outcomes and overall well-being within communities globally, emphasizing the importance of proactive healthcare measures in combating prevalent health challenges.
To learn more about this report, View Report Sample
The market encompasses various diagnostic tools and techniques used for the early detection of HIV, Gonorrhea, Syphilis, Genital herpes, Human immunodeficiency virus (HIV) related diseases such as AIDS, Hepatitis C virus, Human papillomavirus (HPV), malaria, tuberculosis, and other sexually transmitted infections. This market includes laboratory testing in hospitals and clinics, diagnostic centers, centralized laboratories, decentralized Point of Care (POC) testing, home-based tests, and research institutes. Technological advancements have significantly impacted the STD diagnostics market, enabling faster, more accurate, and less invasive testing methods. Raising awareness about early disease detection is crucial for effective treatment and prevention of the spread of these diseases. The STD diagnostics market, with a particular focus on Syphilis Testing, is projected to experience substantial growth in the coming years. This expansion is driven by the rising incidence of sexually transmitted diseases (STDs), including Syphilis, and the continuous advancements in diagnostic technologies and research.
The increasing prevalence of STDs is the key factor driving the global market growth. The market encompasses various Infectious Diseases, including HIV, Gonorrhea, Syphilis, Hepatitis C virus, Human papillomavirus (HPV), and others. According to the Global HIV AIDS Statistics from the World Health Organization, an estimated 0.7% of the global population aged 15-49 years was diagnosed with HIV in 2020. Centralized laboratories and decentralized Point-of-Care (POC) testing are crucial in detecting these diseases early.
Moreover, key players in the market include Quest Diagnostics, Instruments, Reagents and kits manufacturers, and diagnostic centers. Technological advancements have led to the development of home-based tests for safe and discreet STD trials. Hence, the increasing incidence and prevalence of STDs in several countries across the globe are expected to foster the growth of the global market during the forecast period.
The increasing involvement of various organizations to create awareness about STDs will fuel the global market growth. Health Organizations prioritize early detection and screening of infectious diseases like HIV, Gonorrhea, Syphilis, and others. POC trials for HIV, a preferred method, is implemented to overcome patient and provider barriers, with self-trials gaining popularity in developed countries. The market also witnesses progress in molecular diagnostics for STDs. Centralized laboratory trials in hospitals and clinics and decentralized POC testing using sensors, microsystems, and imaging technologies contribute to enhanced outcomes.
However, unfavorable reimbursement policies and reluctance due to fear, stigma, and privacy concerns hinder market growth. Key players include Quest Diagnostics, providing instruments, reagents, and kits for Human immunodeficiency viruses (HIV), Hepatitis C virus, and Human papillomavirus. Government initiatives and home-based tests aim to spread awareness and reduce cases of STDs, encouraging safe sexual intercourse and addressing contaminated and unclean practices. The growing involvement of various organizations to increase awareness about STDs is expected to increase the demand for STD trials drugs and thereby expected to increase the growth opportunity for the global market during the forecast period.
The limited healthcare services in developing regions are a major challenge to the global market growth. The global market is of significant importance in the context of infectious diseases such as HIV, Gonorrhea, Syphilis, and Hepatitis C virus. According to AIDS and Behavior, over 32 million people were living with HIV in 2017, with 5.4 million in the Asia-Pacific region and over 25 million in Africa. The scarcity of financial and human resources for medical care in developing regions, including Asia and MEA, hinders the promotion of public health and results in high STD-infected populations.
Moreover, the healthcare systems in these countries often lack skilled healthcare professionals and quality health services, including STD trials. Point-of-care (POC) trials is a technological advancement that aims to address this issue by providing early disease detection at decentralized locations such as hospitals and clinics, diagnostic centers, and even home-based tests. These factors lead to an increased prevalence of HIV, resulting in high rates of mortality and morbidity, which, together with the lack of financial resources for infrastructure and health systems, may hinder the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.- The company offers STD testing services, specifically for the detection of Hepatitis C, to combat chronic liver disease.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The laboratory testing device segment will be significant during the forecast period. The market encompasses various infectious diseases, including HIV, Gonorrhea, Syphilis, Hepatitis C virus, Human papillomavirus, and Chlamydia trachomatis (CT). According to the World Health Organization and Global AIDS Statistics, the highest incidence of Chlamydia infections occurs in individuals aged 15-24 years. Health Organizations highlight the importance of early disease detection to mitigate the spread of these diseases. Point-of-care (POC) testing plays a significant role in STD diagnostics, particularly for CT and Neisseria gonorrhoeae (NG).
Get a glance at the market contribution of various segments View the PDF Sample
The laboratory testing device segment showed a gradual increase in the market share of USD 53.60 billion in 2018. Technological advancements have led to decentralized POC testing, enabling diagnostics in hospitals and clinics, diagnostic centers, and even at home. However, unfavorable reimbursement structures and reluctance toward testing due to fear, stigma, privacy concerns, and the contaminated nature of samples pose challenges to market growth. Major players in the STD diagnostics market include Quest Diagnostics, Instruments, Reagents, and kits manufacturers. Human immunodeficiency virus (HIV), AIDS, and Behavior, and Public Health initiatives promote safe sexual intercourses and spreading awareness to combat the spread of these diseases. Despite these efforts, the increasing number of cases of STDs necessitates continuous innovation and improvement in diagnostics kits and testing technologies.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 48% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America, specifically focused on Sexually Transmitted Diseases (STDs), is predominantly influenced by the US market. Key drivers include the rising prevalence of diseases such as Hepatitis B, HIV/AIDS, HPV, malaria, and tuberculosis. Major players like BD COR MX, Johnson and Johnson, Pfizer, AbbVie, and Abbott contribute significantly to the market due to the availability of diagnostics platforms for negative patient screening and treatment of STDs. At-risk populations, including MSM and pregnant women, are particularly vulnerable to diseases like Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Improved access to healthcare coverage through initiatives like the Affordable Care Act is enhancing the reach of STD trials and treatment for conditions like HIV/AIDS and AIDS. Hence, such factors are driving the market in North America during the market research and growth period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market is a significant segment of the global healthcare industry. With the increasing awareness and acceptance of regular health check-ups, the demand for STD testing is on the rise. The market for STD testing is driven by various factors, including the high prevalence of STDs, increasing government initiatives, and growing private sector participation. The market is also witnessing the entry of new players and technological advancements, leading to innovative testing methods and improved accuracy. The market for STD testing includes various diagnostic techniques such as nucleic acid amplification tests (NAATs), diagnostics platform, pregnancy complications, increased risk of HIV, culture-based methods, and rapid diagnostic tests (RDTs). The market is segmented by diseases, including Chlamydia, Gonorrhea, Syphilis, HIV, and others. The market for STD testing is expected to grow at a significant CAGR during the forecast period. The market is also witnessing the emergence of PointofCare Testing, which is gaining popularity due to its convenience and quick turnaround time. The market for STD testing is a crucial component of disease management and prevention efforts, and it plays a vital role in ensuring public health and safety.
Market Scope |
|
Report Coverage |
Details |
Page number |
176 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.6% |
Market Growth 2024-2028 |
USD 32.37 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.22 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 48% |
Key countries |
US, Germany, UK, Canada, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., AccuBioTech Co. Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt. Ltd., CTK Biotech Inc., Everlywell Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Goffin Molecular Technologies, Hangzhou Biotest Biotech, Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., LT Labs, Merck and Co. Inc., Ok Biotech Co Ltd., Priority STD Testing, QIAGEN NV, and RayBiotech Life Inc. |
Market dynamics |
Parent market growth analysis, Market Forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Disease Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.